KNOWLEDGE BANK

Interviews

How can bioprinting enable better drug discovery?

CEO, Axolotl Biosciences
Dr Stephanie Willerth is a biomedical engineer entrepreneur and thought leader in D bioprinting and neural tissue engineering As CEO of Axolotl Biosciences and a Full Professor at the University of Victoria she leads innovations in personalized medicine through bioink development and human tissue models Her work bridges academia and industry bringing groundbreaking research into realworld healthca...

Articles

Precision medicine for Alzheimer’s Disease

Alzheimers disease a common cause of dementia is characterised by deposition of senile plaques and neurofibrillary tangles These protein deposits are inherent key features of AD distinguishing from other types of dementia AD also notably marks with neuroinflammation oxidative stress

Research Insights

Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines

Thelma E Tupasi Rajesh Gupta Ma Imelda D Quelapio Ruth B Orillaza Nona Rachel Mira Nellie V Mangubat Virgil Belen Nida Arnisto Lualhati Macalintal Michael Arabit Jaime Y Lagahid Marcos Espinal Katherine Floyd

Case Studies

Tablet Coating at Low Bed Temperatures with a Novel Coating Polymer

This study shows how to obtain elegant uniform coatings with zero visible defects and a practical coating solution for heat sensitive products For More Infromation Click Here

Techno Trends

World's Fist-of-its-Kind Drug Delivery Device Launched for Precise Dosing of Cannabis

Syqe Medical launched the worlds first pharmaceuticalgrade metereddose cannabis inhaler in Israel The eight years of research and development including rigorous testing through multiple clinical trials paved a novel regulatory path

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Novel Claudin Targeted C-terminal Clostridium Perfringens Enterotoxin Conjugated Anticancer Nanotherapeutics

Sushil Y. Raut

Sushil Y. Raut Assistant Professor and Head of Research Promotion Cell, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.

 

Tanaji D. Nandgude

Tanaji D. Nandgude, Associate Professor, Dr. D. Y. Patil institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has 15 years of experience in teaching and research in pharmacy. He has more than 50 research/review papers, more than 60 research paper presentations, 5 book publications and granted projects to his credit. He is recipient of “Young Researcher Award”.

 

2

The Emergence of Organ-on-chips for Diseases Studies and Drug Development

Giuseppe Maruccio

Giuseppe Maruccio is Full Professor at Department of Mathematics and Physics – University of Salento and head of Omnics Research Group which comprises researchers with different backgrounds from physics to life sciences working in cross-disciplinary areas  with applications from -onics (electronics, spintronics and magnonics) to -omics technologies (genomics, proteomics and cellomics)

 

Anna Grazia Monteduro

Anna Grazia Monteduro is researcher at Department of Mathematics and Physics - University of Salento in Lecce (Italy) and carries out her research activity within Omnics Research Group in the fields of (i) sensors, lab on chip and organ on chip; (ii) Nanoelectronics, spintronics, nanomagnetism and applied superconductivity.

 

Silvia Rizzato

Silvia Rizzato is researcher at the Department of Mathematics and Physics - University of Salento and carries out her research activity within Omnics Research Group on the development of new devices and processes for sensing and spintronics, including surface acoustic waves devices, electrochemical sensors and colloidal lithography for LSPR sensors.

 

Giusi Caragnano

Giusi Caragnano is a PhD student in Nanotechnologies at the University of Salento - CNR Nanotec and she is part of the Omnics Research Group. Her research activity concerns development of the Organ-on-chip to support the treatment of both chronic and cancerous gastrointestinal diseases

 

3

Chemistry & AI

Ashok Kumar

Dr. Ashok Kumar FRSC, President of the Centre for Research & Development at Ipca, earned his PhD from CDRI with Dr. Nityanand and post-doctoral experience from Sussex University with Nobel Laureate Prof. Cornforth. His interests include Chemical, Biotechnological & NDDR research and also integrating spirituality, philosophy, and common sense in his professional and personal life.

4

The Therapeutics Landscape of Miniproteins

Victor H Bustos

Victor H. Bustos, Ph.D., is the Vice President of Preclinical R&D at Ordaos Bio. A specialist in protein engineering with a doctorate in Biomedicine, he leads the design of AI-generated mini-proteins. Previously, he spent 17 years at Rockefeller University focusing on complex cellular mechanisms and therapeutic target validation.

Alena Romanova

Alena Romanova is a Scientist I at Ordaos Bio, where she develops experimental workflows for protein characterisation and biologics discovery, including the application of cell-free protein expression and biochemical assays.

5

When Orphan Drugs Make All the Difference

Sue Lee

Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.

press releasesRead more...

Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product

Alteogen Inc KOSDAQ a leading biopharmaceutical company specializing in platform technologies announced today that it has entered into an exclusive license agreement with a global pharmaceutical company

Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea

Adneuris Therapeutics a wholly owned subsidiary of Tris Pharma advancing a new kind of pain medicine today announced that it has entered into an exclusive license agreement with Maruishi Pharmaceutical Co Ltd

Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

Recently Porton Advanced Solutions Ltd Porton Advanced has officially been granted a Drug Manufacturing License Class C by the National Medical Products Administration NMPA This milestone qualifies Porton

QIMR Berghofer and James Cook University boost strategic partnership to advance tropical health research and workforce development

QIMR Berghofer and James Cook University JCU have strengthened their strategic partnership to create one of Australias leading collaborations in tropical health research accelerating the development

NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing

NueCell Bio a newly established cell therapy science and development services company that utilizes proprietary modular translational development solutions focused on advancing modern cell therapies

Alphamab Oncology Announces NDA for Anbenitamab (KN026) in Combination with HB1801 as Neoadjuvant Treatment for HER2-Positive Breast Cancer Accepted by NMPA and Granted Priority Review

Alphamab Oncology stock code HK today announced that the New Drug Application NDA for Anbenitamab brand name KN a HER bispecific antibody independently developed

EventsRead more...

11 - 12

Aug 2026

19 - 21

Aug 2026

20 - 21

Aug 2026

20 - 21

Aug 2026

20 - 21

Aug 2026

25 - 27

Aug 2026

CPHI Korea 2026

COEX, Seoul, Korea

26 - 27

Aug 2026

BIOMEDevice 2026

Boston Convention & Exhibition...

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

LATEST NEWSRead more...

GenScript and Tamarind Bio partner to link AI molecular design with wet-lab validation

GenScript Biotech Corporation and Tamarind Bio have entered into a strategic partnership to combine AIpowered molecular design with rapid wetlab validation aiming to streamline the drug discovery process

Phylo and Chugai collaborate to deploy AI platform for drug discovery

Phylo has entered into a collaboration with Chugai Pharmaceutical to deploy Biomni Lab its agentic AI platform for biomedical research across Chugais drug discovery programmes

Amplia Enters into Collaboration with Lilly to Evaluate Narmafotinib in Lung Cancer Trial

Amplia Therapeutics has entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to evaluate its investigational focal adhesion kinase FAK inhibitor narmafotinib

Fujifilm and Taiho Pharmaceutical Partner to Advance Next-Generation ADC Manufacturing

FUJIFILM and Taiho Pharmaceutical have formed a strategic partnership to develop manufacturing technologies for nextgeneration antibodydrug conjugates ADCs

CREATE Medicines Expands In Vivo CAR Platform Through Monash University Collaboration

CREATE Medicines has entered into a strategic research collaboration and exclusive licensing agreement with Monash University and its Monash Institute of Pharmaceutical Sciences MIPS to strengthen its targeted in vivo Chimeric Antigen Receptor CAR therapy platform

Kaigene Licenses Autoimmune Therapy KG006 to Taisho Pharmaceutical for Japan

Kaigene a USbased biotechnology company focused on antibody therapies for autoimmune diseases has signed an exclusive licensing agreement with Taisho Pharmaceutical for the development and commercialisation of its nextgeneration human neonatal Fc receptor hFcRn inhibitor